Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Otsuka’s Pharma Sales Down Nearly 15% in 2015
February 15, 2016
- Pfizer’s Metformin 500 mg Fails to Clear Test, Shipment Suspended
February 15, 2016
- Astellas Completes Acquisition of Ocata
February 15, 2016
- Alecensa Japan PIII Trial Halted Early for Benefit
February 12, 2016
- Lilly’s Japan Sales Slip 2% to US$1.9 Billion in 2015
February 12, 2016
- Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
February 12, 2016
- New CSL Japan Chief Eager to See Annual Sales of 40 Billion Yen in 5 Years
February 10, 2016
- Asahi Kasei President to Step Down over Piling Data Scandal
February 10, 2016
- Daiichi Sankyo to Close UK Development Unit
February 10, 2016
- Otsuka Licenses US Rights for PDE4 Inhibitor to Medimetriks
February 10, 2016
- Ethical Drug Sales Up 5.7% in December: Crecon Report
February 10, 2016
- Gilead, Bristol Take Quantum Leaps in 2015, Lilly Logs Double-Digit Growth: IMS
February 10, 2016
- Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
February 10, 2016
- Mundipharma Gearing Up for Full-Blown Oncology Business in Japan
February 9, 2016
- AZ Posts Japan Sales of US$2 Billion in 2015, Down 9% in Actual Terms
February 9, 2016
- Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
February 9, 2016
- PeptiDream Joins Hands with Shionogi, 5th Japanese Partner
February 8, 2016
- Takeda Expands ADC Collaboration with US Startup Mersana
February 5, 2016
- FDA Panel Backs Effectiveness of Brintellix for Cognitive Dysfunction
February 5, 2016
- Mitsubishi Tanabe to Establish Stand-Alone Sales Structure via New US Subsidiary
February 5, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…